论文部分内容阅读
为了解人类重组红细胞生成素(γ-HuEPO)对尿毒症血透病人肾性贫血、脂质代谢的影响,对30例病人用药前后检测血细胞比容(Hct)、血红蛋白(Hb)、促红素(EPO)、叶酸(FOL)、铁蛋白(SF)、血小板生成素(TPO)、维生素B_(12)(Vit B_(12))、血清总胆固醇(CHOL)、甘油三脂(Trig)、载脂蛋白 A(APO A)、载脂蛋白 B(APOB)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)。结果表明γ-HuEPO 治疗后 Hct、Hb、EPO、FOL、TPO、Vit B_(12)含量较治疗前明显增高;对脂质代谢有一定的影响:CHOL、TG、LDL-C 明显下降。APO A、HDL-C 明显增高;EPO 与 CHOL、TG、LDL-C 的含量有一定的相关性。结论:γ-HuEPO 能有效地改善尿毒症血透病人的贫血状态,对脂质代谢紊乱有缓解作用。
To understand the effect of human recombinant erythropoietin (γ-HuEPO) on renal anemia and lipid metabolism in patients with uremia hemodialysis, the levels of hematocrit (Hct), hemoglobin (Hb), erythropoietin (EPO), FOL, SF, TPO, Vit B 12, CHOL, Trig, APO A, APOB, HDL-C, and LDL-C. The results showed that the contents of Hct, Hb, EPO, FOL, TPO and Vit B 12 in the group treated with γ-HuEPO were significantly higher than those before treatment, while the levels of CHOL, TG and LDL-C were significantly decreased. APO A, HDL-C significantly increased; EPO and CHOL, TG, LDL-C content has a certain correlation. Conclusion: γ-HuEPO can effectively improve anemia in patients with hemodialysis of uremia and relieve lipid metabolism disorders.